Results from a new registry of Manhattan, NY, residents has revealed that Asian/Pacific Islanders and Hispanics of any race are more likely to be affected by systemic lupus erythematosus (SLE) than people who are white (Izmirly PM, et al. Arthritis Rheumatol. 2017 Sep 10. Epub ahead of print).

Researchers have developed and validated a new algorithm to use with electronic health records (EHRs) that can accurately identify patients with systemic lupus erythematosus (SLE; Barnado A, et al. Arthritis Care Res [Hoboken]. 2017;69:687-693).

Approximately 1 in 4 patients with systemic lupus erythematosus (SLE) included in a recent study had resting specific electrocardiogram (ECG) abnormalities that predict future cardiovascular events, including myocardial infarction, sudden death, and congestive heart failure (Al Rayes H, et al. Arthritis Res Ther. 2017;19:31).

The majority of patients affected by systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS) are women of childbearing age. Personal relationships and family planning among these patients suffer because of gaps in the management of reproductive concerns (eg, pregnancy’s effect on maternal disease, effects of the disease on the fetus, and medication safety during pregnancy and breast-feeding) and other women’s health issues.

London, United Kingdom—Evidence is mounting in support of using the investigational monoclonal antibody anifrolumab in patients with severe systemic lupus erythematosus (SLE). Results from the phase 2b MUSE trial—which were first presented at the 2015 American College of Rheumatology Annual Scientific Meeting, and then in greater detail at the recent 2016 European League Against Rheumatism Annual Congress—show that in patients with moderate-to-severe SLE, anifrolumab reduces disease activity across a wide range of clinical end points, and is safe and tolerable.
San Francisco, CA—Reductions in postinitiation treatment costs partly offset, but did not eliminate, the added cost of repository corticotropin injection (RCI) therapy for patients with systemic lupus erythematosus (SLE), researchers behind the analysis of an administrative claims database have found.
London, United Kingdom—Women with systemic lupus erythematosus (SLE) appear to have a higher risk for cervical cancer and premalignant cervical changes compared with women in the general population, according to the results of a large Swedish registry study presented at the 2016 annual meeting of the European League Against Rheumatism (EULAR). The highest risk was observed in women treated with immunosuppressive agents compared with those treated with antimalarial medications, the researchers also observed.
Investigators behind a longitudinal study at a single center identified several risk factors for organ damage in patients with systemic lupus erythematosus (SLE), and demonstrated that organ damage compromises health-related quality of life (HR-QOL) in these patients. Factors such as preexisting damage at baseline, age, immunosuppressive drug use, cigarette smoking, and higher mean erythrocyte sedimentation and C-reactive protein (CRP) levels were associated with earlier organ damage; some of these risk factors are modifiable.
Lupus is an autoimmune disease that affects multiple parts of the body, and results in the immune system attacking healthy tissues. Symptoms of lupus, including painful joints, red rash, and extreme fatigue, differ from person to person, and appear in the form of a flare. Although symptoms can worsen despite taking medication, certain steps for preventing lupus flares can be beneficial. The following tips include methods for preventing the onset of a flare.
A recent systematic review suggests that taking action in a variety of nonpharmacologic ways can reduce fatigue associated with systemic lupus erythematosus (SLE).
Page 1 of 5
Results 1 - 10 of 45
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology